Avoiding androgen deprivation therapy in men with high-risk prostate cancer: The role of radical prostatectomy as initial treatment

Urology

Volumn 77, Issue 4, 2011, Pages 946-950

  Miocinovic, Ranko ^a   Berglund, Ryan K ^a   Stephenson, Andrew J ^a   Jones, J Stephen ^a   Fergany, Amr ^a   Kaouk, Jihad ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY;

ADULT; AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79953858695     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.057     Document Type: Article

References (30)

1. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300. (Pubitemid 27318990)
2. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. (Pubitemid 46630983)
3. Saigal CS, Gore JL, Krupski TL. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493-1500. (Pubitemid 47463063)
4. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833-840.
5. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516-2527.
6. Berglund RK, Jones JS, Ulchaker JC, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology. 2006;67(6):1253-1256. (Pubitemid 43818056)
7. Ward JF, Slezak JM, Blute ML. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-756. (Pubitemid 40547200)
8. Carver BS, Bianco FJ Jr., Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176(2):564-568. (Pubitemid 43927886)
9. Freedland SJ, Partin AW, Humphreys EB, et al. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007;109(7):1273-1278. (Pubitemid 46466553)
10. Loeb S, Smith ND, Roehl KA, et al. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007;69(6):1170-1175. (Pubitemid 46891592)
11. Pierorazio PM, Guzzo TJ, Han M, et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology. 2010;76(3):715-721.
12. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008;53(2):253-259. (Pubitemid 350296585)
13. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497-2504.
14. Dreicer R, Klein EA, Elson P, et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol. 2005;23(2):82-86. (Pubitemid 40616297)
15. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138-1142. (Pubitemid 38746819)
16. Clark PE, Peereboom DM, Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57(2):281-285. (Pubitemid 32140804)
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095- 2101. (Pubitemid 40617061)
18. Berglund RK, Masterson TA, Vora KC, et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180(5):1964-1967; [Discussion: 1967-1968].
19. Stratton KL, Chang SS. Locally advanced prostate cancer: the role of surgical management. BJU Int. 2009;104(4):449-454.
20. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188-2194. (Pubitemid 351628628)
21. Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004;172(5 Pt. 2):S52-S56; [Discussion: S56-S57].
22. Xylinas E, Drouin SJ, Comperat E, et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a singlecentre experience. BJU Int. 2009;103(9):1173-1178; [Discussion: 1178].
23. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68(1):121-125. (Pubitemid 44037727)
24. Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer - therapeutic? J Urol. 2008;179(2):408-413.
25. Schumacher MC, Burkhard FC, Thalmann GN, et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008;54(2):344-352.
26. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109(11):2239-2247. (Pubitemid 46801553)
27. Bhojani N, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys. 2010;76(2):342-348.
28. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325-1332. (Pubitemid 38541647)
29. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956-962.
30. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572-578. (Pubitemid 41140332)